Nuvias Appointed a Pan-EMEA Distributor for Juniper Networks
Nuvias has been appointed as a pan-EMEA distributor for Juniper Networks’ full range of high-performance networking, security, data centre and cloud solutions. High-value distribution business Nuvias will support Juniper’s continued growth plans for EMEA, particularly in the mid-to-high end enterprise market.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170906005157/en/
Paul Eccleston, Nuvias (Photo: Business Wire)
Nuvias has designed, together with Juniper, a full channel partner development and acceleration programme that complements Juniper’s existing channel programme. It will offer technical, sales and marketing training to help maximise the business opportunities in high growth markets such as cloud, Internet of Things (IoT) and Software Defined Networking (SDN) - areas where Juniper also invests.
Nuvias will work with Juniper to identify key vertical markets and geographies for partners and provide them with the skills to transform their customers’ data centres with Juniper’s next-generation networking and security platforms. Nuvias will focus on partner recruitment, accreditation and sales enablement, providing value-added services such as solution events, training, lead generation, and campaign materials.
“Nuvias is excited by this new partnership with Juniper, a pioneer in networking innovation, performance and security. The strength of our commitment will be demonstrated through a dedication to partner enablement, services and solutions that can generate new opportunities and business,” said Paul Eccleston, CEO of Nuvias.
“We are equipping partners with the necessary skills to pursue opportunities independently, generate additional revenues, and deliver innovative services to their customers. Juniper invests in partners that bring in new business and this agreement presents a fantastic opportunity for the channel.”
High-performance network automation, SDN and intelligent, software-defined security will play a key role in organisations’ Digital Transformation strategies, and together Juniper Networks and Nuvias will help partners take advantage of the burgeoning opportunity.
“We are delighted to be working with Nuvias, whose strengths in value-added networking and security distribution perfectly complement our strategic focus and solutions portfolio,” said Kristian Kerr, head of channel, alliances & commercial, EMEA, Juniper Networks. “Nuvias’ approach reflects the dynamic IT landscape, while being able to consistently deliver the highest levels of capability, accreditation, sales, marketing, services and operational excellence to Juniper’s partners across EMEA.”
About Nuvias Group
Nuvias Group is the pan-EMEA, high value distribution business which is redefining international, specialist distribution in IT. The company has created a platform to deliver a consistent, high value, service-led and solution-rich proposition across EMEA. This allows partner and vendor communities to provide exceptional business support to customers and enables new standards of channel success.
The Group’s portfolio covers a comprehensive range of IT solutions, with the focus currently on three areas - Cyber Security (based on the former Wick Hill); Advanced Networking (based on the former Zycko) and Unified Communications (based on the former SIPHON). In July 2017, Nuvias added Benelux value added distributor and security specialist DCB to the Group. All four award-winning companies had previously demonstrated their ability to provide innovative technology solutions from world-class vendors, and deliver market growth for vendor partners and customers. Nuvias Group has 21 regional offices across EMEA, as well as serving additional countries through those offices. Turnover is in excess of US$ 350 million.
For further press information, or photo of Paul Eccleston or Kristian Kerr, please contact Annabelle Brown.
+44 (0)1326 318212
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom